tbuckley/cabot-search huggingface dataset:
Drug abuse in schizophrenic patients: clinical correlates and reasons for use
Authors: L Dixon, G Haas, P J Weiden, J Sweeney, A J Frances
Journal: American Journal of Psychiatry (1991)

This study aimed to 1) determine substance abuse prevalence and preference in a diverse sample of schizophrenic, schizoaffective, and schizophreniform inpatients, 2) compare drug-abusing and non-drug-abusing patients on demographic and clinical variables during the acute and stabilization phases of their hospital course, and 3) obtain data from patients on reasons for drug abuse and on acute state-related changes during periods of intoxication.Eighty-three psychotic inpatients consecutively admitted to a New York City teaching hospital were evaluated. Sixty-eight had schizophrenia, 12 had schizoaffective disorder, and three had schizophreniform disorder diagnosed according to the Structured Clinical Interview for DSM-III-R. Each patient received ratings on the Brief Psychiatric Rating Scale, the Global Assessment Scale, and the Scale for the Assessment of Negative Symptoms at admission and at discharge, an evaluation of premorbid adjustment, and an extensive interview on drug and alcohol use.Forty (48%) of the patients received diagnoses of drug or alcohol abuse or dependence. The drug-abusing patients primarily used cannabis (N = 26), alcohol (N = 21), and cocaine (N = 14) and reported that they abused drugs to get "high," to relieve depression, and to relax. They had significantly fewer positive and negative symptoms at discharge, better sexual adjustment and worse school performance during adolescence, and more family histories of drug abuse than the non-drug-abusing patients.Schizophrenic patients who abuse drugs may represent a subgroup of patients with better prognoses and less severe clinical characteristics of schizophrenia, but their drug abuse may adversely affect global outcome.
A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation
Authors: Mohamed Shanavas, Hans A. Messner, Suzanne Kamel-Reid, Eshetu G Atenafu, Vikas Gupta, John Kuruvilla, Dennis Dong Hwan Kim, Jieun Uhm, Anna Lambie, Laura Ellis, Jeffrey H. Lipton
Journal: Blood (2013)
Abstract 14183: Effectiveness of Serum Tenascin-C Level in Predicting Long-term Prognosis After Acute Myocardial Infarction Treated With Successful Percutaneous Coronary Intervention
Authors: Akira Sato, Michiaki Hiroe, Toshihiro Nozato, Hiroyuki Hikita, Kyoko Imanaka-Yoshida, Kazutaka aonuma
Journal: Circulation (2010)
In Vivo 3-Dimensional Strain Mapping of the Optic Nerve Head Following Intraocular Pressure Lowering by Trabeculectomy
Authors: Michaël J.A. Girard, Meghna R. Beotra, Khai Sing Chin, Amanjeet Sandhu, Monica Clemo, Eleni Nikita, Deborah S. Kamal, Maria Papadopoulos, Jean Martial Mari, Tin Aung, Nicholas G. Strouthidis
Journal: Ophthalmology (2016)
Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease
Authors: Henry Lik-Yuen Chan, Sang Hoon Ahn, Ting-Tsung Chang, Cheng-Yuan Peng, David K. Wong, Carla S. Coffin, Seng Gee Lim, Pei-Jer Chen, Harry L. Janssen, Patrick Marcellin, Lawrence Serfaty, Stefan Zeuzem, Wenhua Hu, Linda Critelli, Juan Carlos Lopez-Talavera, Elizabeth L. Cooney
Journal: Hepatology (2012)
Some Biologic Characteristics of Transplantable Lines of Mouse Adenocarcinomas of the Colon&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Diana M. Cowen, John A. Double, Philip N. Cowen
Journal: JNCI Journal of the National Cancer Institute (1980)

During a 5-year period colon tumors induced by 1,2-dimethylhydrazine dihydrochloride treatment in NMRI mice were transplanted sc into isologous mice to obtain transplantable tumor lines that might serve as experimental models for human colon cancer. The resultant 17 serially transplantable tumor lines were adenocarcinomas varying in degree of differentiation and mucin production. Two of the lines passaged for 5 years and used in chemotherapy studies have shown histologic progression toward dedifferentiation with concomitant acceleration of growth rate.
A phase I study with CRx-026, a novel dual action agent, in patients (pts) with advanced solid tumors
Authors: D. D. von Hoff, M. Gordon, J. Turner, E. White, M. J. Nichols, P. J. Elliott, D. Mendelson
Journal: Journal of Clinical Oncology (2005)

3073 Background: CRx-026 contains two active pharmaceutical ingredients which, when combined, synergistically blocks cancer cell division by inhibiting two critical elements of the cancer cell’s mechanism for dividing. One component of CRx-026, chlorpromazine, inhibits hsEg5/KSP, a mitotic kinesin essential for centrosome separation. The other component, pentamidine, is reported to inhibit PRL phosphatases, which play an important role in regulating mitotic progression and proper chromosome separation. The objectives of this Phase I study were to assess the dose limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD), and to describe the pharmacokinetics (PK) of CRx-026 in patients with advanced solid tumors. Methods: 18pts with metastatic cancer whose tumors had progressed on at least one prior therapy were enrolled in escalating dose-level (DL) cohorts in a ‘3+3’ design. The pts received CRx-026 by infusion daily for 5 consecutive days. After a 16-day therapy-free interval (one cycle) the treatment was repeated. Evaluation for response was performed every 2 cycles. EKG monitoring and PK analysis were done during cycle one only. Results: Standard Phase I eligibility criteria were required for patient entry. The pts (median age: 61yrs; 13M/5F) were treated at 4DLs: DL1 (7pts); DL2 (3pts); DL3 (6pts); DL4 (2pts). WHO PS: 0 (7pts.), 1 (11pts.). The DLTs included one dystonic reaction and one supraventricular tachycardia at DL4. The other common toxicity was somnolence which occurred during the infusion but this was not dose limiting. No CRs or PRs have been observed to date. 6pts have shown stable disease ranging from 4–8+ cycles. The median duration on study showed a trend toward longer duration at higher dose levels. The MTD for this trial is DL 3. The PK profile of CRx-026 was linear over the dose range studied. The PK parameters of the components of CRx-026 did not appear to differ from known literature values indicating an absence of drug-drug interactions. Conclusions: CRx-026 represents a different approach to hitting a pattern of targets in cancer cells. CRx-026 can be safely given in pts with advanced cancer. DL3 is the recommended Phase II dose on this schedule to assess its clinical activity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration CombinatoRx CombinatoRx CombinatoRx CombinatoRx
High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up
Authors: E. Aoki, H. Kantarjian, S. O’Brien, M. Talpaz, F. Giles, G. Garcia-Manero, W. Wierda, S. Verstovsek, D. Jones, R. Luthra, J. Cortes
Journal: Journal of Clinical Oncology (2006)

6535 Background: The standard dose (SD) of imatinib for CP CML is currently 400 mg daily, but higher doses (HD) may be more effective. We conducted 2 consecutive trials using HD imatinib (i.e., 400mg twice daily) in previously untreated early CP CML pts. This is an updated analysis of the longer follow-up. Methods: A total of 175 previously untreated pts received HD imatinib. We compared the results with a previous study using SD imatinib (400mg/day) in untreated pts with early CP CML (N=50). Results: Cytogenetic and molecular responses were evaluable in 222 pts (N=49 at SD, 173 at HD) and 217 pts (N=46 at SD, 171 at HD), respectively. In HD group, Sokal risk classification was good in 69%, intermediate in 29%, and poor in 11% of pts. There were no differences in pre-treatment characteristics between two groups. The median age was 48 years in both groups. Median follow-up is 53 months for SD and 30 months for HD group. Patients treated with HD had a higher rate of complete cytogenetic responses (90% vs 78% with SD, p=0.03) and these occurred earlier, with 69% achieving this response after 6 months of therapy vs 45% with SD (p=0.001). The cumulative incidence of major molecular response was significantly better in HD group (p=0.03), and this response was also observed earlier in HD group: at 12 months 54% in HD and 24% in SD group had achieved this response (p=0.001). At 24 months, 19/70 (27%) evaluable pts with HD versus 3/31 (10%) of pts in SD group achieved complete molecular remission. Four pts (2%) in HD group and 4 pts (8%) in SD group have progressed to advanced phases (p=0.05). There was a trend in favor of the HD group for transformation-free-survival but it was not statistically significant (p=0.07). Overall survival is excellent in both groups (24 month survival, 99% with HD vs 98% with SD; p=0.24). Grade 3 or 4 hematologic toxicity was more frequent in HD group whereas extramedullary toxicity was similar in two groups. The median actual dose in HD group was 800 mg at 12 months, with 39% patients requiring dose reduction at some point. Conclusions: High-dose imatinib provides higher rates of complete cytogenetic responses and earlier molecular responses with some increase myelosupression. The long-term benefit of earlier responses remains to be demonstrated. [Table: see text]
Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer
Authors: Kim C. Aalders, Emily L. Postma, Luc J. Strobbe, Margriet van der Heiden-van der Loo, Gabe S. Sonke, Liesbeth J. Boersma, Paul J. van Diest, Sabine Siesling, Thijs van Dalen
Journal: Journal of Clinical Oncology (2016)

Purpose The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes. Patients and Methods Women &lt; 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were estimated by using Kaplan-Meier statistics. Results A total of 1,000 patients were identified, of whom 59% had a known subtype: 39% HR-positive/HER2-negative; 17% HR-positive/HER2-positive; 10% HR-negative/HER2-positive; and 34% HR-negative/HER2-negative (triple negative). Overall 5-year LR and RR rates were 3.5% and 3.7%, respectively. A decreasing trend for both rates was observed over time and was accompanied by a significant decrease in the risk of distant metastases (DM). LR occurred in 4.2%, RR in 6.1%, and DM in 17.8% of patients in 2003, and in 3.2%, 4.4%, and 10.0%, respectively, in 2008. LR and RR rates varied with biomarker subtype. These differences were borderline significant when analyzed for the entire study period (P = .056 and P = .014, respectively) and leveled off after the introduction of trastuzumab after 2005 (P = .24 and P = .42, respectively). Patients with lymph node metastases at the time of diagnosis had an increased risk of RR. The type of surgery performed—breast-conserving or mastectomy—did not influence rates of LR and RR. Conclusion Overall, the rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied by biomarker subtype.
Detection of Tn Antigen With &lt;italic&gt;Vicia villosa&lt;/italic&gt; Agglutinin in Urinary Bladder Cancer: Its Relevance to the Patient's Clinical Course
Authors: T Nishiyama, Y Matsumoto, H Watanabe, M Fujiwara, S Sato
Journal: JNCI Journal of the National Cancer Institute (1987)

Recently, several investigators have demonstrated that the MN blood group precursor antigens Thomsen-Friedenreich antigen (T-Ag) and Tn-antigen (Tn-Ag) are expressed on the cell surfaces of several cancers, including urinary bladder cancer. T-Ag is composed of a specific carbohydrate chain, galactose-beta-1-3-N-acetylgalactosamine (GalNAc), which is specifically detectable through the immunohistochemical binding of peanut agglutinin (PNA). In normal cells, T-Ag is cryptic (cT-Ag) and can be unmasked by treatment with neuraminidase. Tn-Ag is composed of another carbohydrate chain, alpha-GalNAc-serine/threonine, and binds specifically to Vicia villosa agglutinin (VVA). With the use of both these lectins, VVA and PNA, the presence or absence of Tn-Ag and T-Ag was examined in 24 specimens of normal bladder epithelium and specimens from 53 cases of human urinary bladder transitional cell carcinoma of various histologic grades by staining paraffin sections by means of the avidin-biotin-immunoperoxidase technique. The correlation between the expression of these antigens and the patient's clinical course was then estimated. Out of 21 patients in whom the tumors expressed the phenotype Tn-Ag(+), T-Ag(+), or cT-Ag(-), 17 suffered from invasive recurrence. Although patients with tumors expressing the phenotypes T-Ag(-) and cT-Ag(+) have been reported to show a good clinical course, in our studies some of them showed a switch to invasive recurrence. Thus it was not possible to estimate the patient's clinical course only by the presence or absence of T-Ag and cT-Ag. The expression of Tn-Ag was then examined with the use of VVA. Of 38 cases expressing the phenotypes T-Ag(-) and cT-Ag(+), 6 had tumors that carried Tn-Ag; 5 of them suffered from invasive recurrence. These results indicated that the detection of Tn-Ag with the use of VVA in combination with the examination of T-Ag and cT-Ag is useful for estimating the degree of malignancy of bladder cancer and the patient's clinical course.
Delirium induced by topical application of podophyllin: a case report
Authors: A Stoudemire, N Baker, T L Thompson
Journal: American Journal of Psychiatry (1981)

The authors describe a patient who developed delirium secondary to the topical absorption of podophyllin; this may be the first known case of delirium after topical application of the drug. Other serious medical and neurological complications of podophyllin poisoning are also discussed.
Surgical resection for pancreatic cancer: Correlates of margin positivity
Authors: S. Ashraf, C. Andrews, B. Kuvshinoff, A. Pande, M. Javle, J. F. Gibbs
Journal: Journal of Clinical Oncology (2006)

4097 Background: Positive surgical margins (PSMs) occur in 20–40% of pancreatic cancer cases treated surgically. PSMs are associated with local recurrence and poor survival. Objectives: Correlate clinicopathological parameters with PSMs in pancreatic cancer patients (pts) undergoing surgical resection. Methods: Clinicopathological data for 71 pts who underwent surgical resection for pancreatic cancer from 1999–2005 were obtained. Data including location, AJCC stage, tumor size, type of resection, use of neoadjuvant therapy, grade, morphology, perineural and angiolymphatic invasion were correlated with PSMs and survival using logistic regression, Fisher-exact test and log-rank test. Results: There were 29 males; median age was 65 years and median follow-up 14 months. Histologies were: adenocarcinoma (n = 67), sarcomatoid (n = 2), adenosquamous (n = 1) and mucinous cystadenocarcinoma (n = 1). Sites of disease were: head only (n = 56), head/uncinate (n = 7) and body/tail (n = 8). Surgical treatments included Whipple (n = 43), pylorus preserving Whipple (n = 18) distal pancreatectomy (n = 8) and total pancreatectomy (n = 2). Pathological AJCC stages were: ΙA (n = 4), ΙB (n = 2), ΙΙA (n = 14), ΙΙB (n = 48), and ΙΙΙ (n = 3). Neoadjuvant chemoradiation (CRT) was administered in 10 cases; 38 other pts received postoperative adjuvant therapy including CRT (n = 36)/chemotherapy only (n = 2). Overall median survival was 30 months and disease free survival 18.6 months. Nineteen cases (27%) had PSMs. PSMs were pancreatic transection line (n = 11), retroperitoneal margin (n = 9), bile duct (n = 1) and peripancreatic soft tissue (n = 2). On univariate analysis, PSM was associated with advanced AJCC stage (p = 0.02) and tumor location other than pancreatic head (p = 0.02). PSM rate was 10% (1/10) and 31% (18/61) for pts with/without neoadjuvant therapy, respectively (p = 0.27). On multivariate analysis, PSM correlated with AJCC stage (p = 0.04) and tumor location (p = 0.05). PSMs were not significantly related to survival or recurrence (p = 0.09). Conclusions: Advanced AJCC stage and tumor in pancreatic body/tail or uncinate are associated with PSMs following pancreatic cancer resection. Strategies to “downstage” with novel therapies prior to surgery should be investigated to facilitate a complete surgical resection. [Table: see text]
Endoscopic treatment of food intolerance after a banded gastric bypass: inducing band erosion for removal using a plastic stent
Authors: Josemberg Marins Campos, Rena Moon, Galeno Magalhães Neto, Andre Teixeira, Muhammad Jawad, Lyz Bezerra Silva, Manoel Neto, Álvaro Ferraz
Journal: Endoscopy (2016)

<b>Background and study aims:</b> Ring complications after a banded Roux-en-Y gastric bypass (RYGB) are usually managed surgically. The aim of this study was to analyze the safety and effectiveness of endoscopic removal of noneroded rings after banded-RYGB, by inducing intragastric erosion of the ring using a self-expandable plastic stent (SEPS). <b>Patients and methods</b>: A total of 41 patients with banded RYGB who had noneroded rings and food intolerance were prospectively enrolled. Patients were treated with endoscopic SEPS placement and ring removal. Data from time of stenting, resolution of symptoms, need for endoscopic dilation, and complications were recorded. <b>Results:</b> Successful ring removal was possible in all patients. In 21 cases, the SEPS induced complete erosion, and in 17 cases the ring was removed a month later because of incomplete erosion at the time of SEPS removal. Nine patients (22.0 %) needed endoscopic dilation after stent removal in order to treat fibrotic strictures. Food tolerance was observed in 32 patients (78.0 %) after the procedure. No patient needed surgery and there were no deaths. <b>Conclusions:</b> Endoscopic removal of the ring using SEPS appeared to be safe and effective after a banded RYGB.
Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia
Authors: Francesca M Russo, Jaan Toelen, M Patrice Eastwood, Julio Jimenez, Andre Hadyme Miyague, Greetje Vande Velde, Philip DeKoninck, Uwe Himmelreich, Patrizia Vergani, Karel Allegaert, Jan Deprest
Journal: Thorax (2016)

<h3>Introduction</h3> The management of congenital diaphragmatic hernia (DH) would benefit from an antenatal medical therapy, which addresses both lung hypoplasia and persistent pulmonary hypertension. We aimed at evaluating the pulmonary effects of sildenafil in the fetal rabbit model for DH. <h3>Methods</h3> We performed a dose-finding study to achieve therapeutic fetal plasmatic concentrations without toxicity following maternal sildenafil administration. Subsequently, DH fetuses were randomly exposed to transplacental placebo or sildenafil 10 mg/kg/day from gestational day 24 until examination at term (day 30). Efficacy measures were ipsilateral pulmonary vascular and airway morphometry, micro-CT-based branching analysis, Doppler flow in the main pulmonary artery and postnatal lung mechanics. <h3>Results</h3> Fetal sildenafil plasmatic concentration was above the minimal therapeutic level for at least 22 h/day without maternal and fetal side effects. The placebo-exposed DH fetuses had increased wall thickness in peripheral pulmonary vessels and significantly less fifth-order vessels compared with controls (CTR). Sildenafil-exposed DH fetuses, instead, had a medial and adventitial thickness in peripheral pulmonary vessels in the normal range and normal vascular branching. Fetal pulmonary artery Doppler showed a reduction of pulmonary vascular resistances both in DH and in CTR fetuses treated by sildenafil compared with the placebo-treated ones. Sildenafil also reversed the mean terminal bronchiolar density to normal and improved lung mechanics, yet without measurable impact on lung-to-bodyweight ratio. <h3>Conclusions</h3> In the rabbit model for DH, antenatal sildenafil rescues vascular branching and architecture, reduces pulmonary vascular resistances and also improves airway morphometry and respiratory mechanics.
Intra-hepatic lipiodol I 131 combined with oxaliplatin, infusional FUDR, leucovorin in hepatocarcinoma and hepatic metastasis
Authors: F. P. Costa, R. Schemerling, O. F. Costa, P. A. Costa, C. Albertotti, S. Martins, A. C. Buzaid, F. Maluf, I. Mayer, R. Marques
Journal: Journal of Clinical Oncology (2004)

4133 Background: We conducted a pilot study with L131 internal hepatic radiation combined with IA OHP, infusion FUDR and LV in 19 AHC and 20 HM pts, to assess feasibility, response rate, symptom relief, TTP and 1-year OS. Methods: Median age was 60 yo (20 - 76), 32 pts were male. All pts had predominant hepatic disease and symptomatic progression prior to inclusion. Portal vein thrombosis was documented in 3 pts. KPS was 70% in 4 pts and ≥ 80% in 35 pts. All HM and 10 out of 19 AHC pts have had prior treatment (range: 1–9). Out of 19 AHC pts, 12 were Child-Pugh A, 7 were B and 2 were C. Out of 20 HM, 14 were colorectal tumors. All pts were assigned to receive only one treatment. However, re-treatment was allowed after documented liver progression by CT or MRI in responders or to reach a tumor radiation dose ≥120 Gy. Therapy was a single L131 intra-hepatic infusion dose followed by OHP 100 mg/m2 IA over 2h on D1, and FUDR 60 mg/m2/d + LV 15 mg/m2/d IA by 96h infusion (D1–4). G-CSF SC was given from D5–15. The L131 dose was planned for each pt in order to deliver > 120 Gy to tumor mass and < 50 Gy to normal liver parenchyma. To date, 45 treatments were delivered (whole liver - 20; R lobe - 15; L lobe - 3). 6 pts got more than one treatment. The L131 median dose was 50 mCi (range: 25 - 80). Results: All pts developed severe fatigue post-procedure lasting 7 to 14 days. Other grade III/IV toxicity included thrombocytopenia (28%), elevation of liver enzymes (17%), neutropenia (15%), enteritis (11%), diarrhea (8%), hepatic encephalopathy (8%), mucositis (6%) and fever (4%). No clinical benefit was observed in Child B and C AHC pts. 2 AHC had treatment related death (liver failure and gastric bleeding). 3 other pts (1 HM, 1 Child B and 1 Child C AHC) died within 60 days of therapy due to PD. Conclusion: ICM is a feasible and active in refractory AHC and HM pts. An improved TTP trend was observed for AHC (p=0.057). A phase II study is ongoing for HM and AHC pts, restricted to Child-Pugh A. No significant financial relationships to disclose.
Abnormalities Of FAM46C, AHCYL1, CDC14A and CDKN2C Genes Located At Chromosome 1p Detected By QM-FISH Identifies Deletion Of 1p32.3 Covered CDKN2C Is An Independent Adverse Prognostic Marker In Multiple Myeloma
Authors: Fei Li, Li-ping Hu, FengYan Jin, Yan Xu, Gang An, Zengjun Li, Mei-rong Zang, Shu-hui Deng, Dehui Zou, Hong Chang, Lugui Qiu
Journal: Blood (2013)